Breaks Categories: News

ThursdayAug 15, 2024 12:32 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Q2 2024 Financial Report, Operational Update

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, is reporting on financial and operations results for its second quarter 2024, the period that ended June 30, 2024. Highlights of the report include steady progress made toward key clinical and regulatory milestones on its HeartBeam AIMIGo(TM) System, including the 510(k) submission to the U.S. Food and Drug Administration (FDA); the report also noted that the company has completed two presubmission meetings with the FDA regarding the company’s planned 510(k) submission of its 12-lead synthesis software. “The second quarter of 2024 was…

Continue Reading

ThursdayAug 15, 2024 11:52 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Publishes Q2 2024 Results

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today released its financial results for the second quarter ended June 30, 2024 (“Q2 2024”). The company also discussed the clinical development progress of Berubicin, its lead program, and TPI 287, its recently in-licensed abeotaxane for the treatment of brain malignancies. CNS Pharmaceutical expects to be able to release final topline data from its potentially pivotal trial of Berubicin in the first half of 2025. The trial is evaluating Berubicin in adult patients with…

Continue Reading

ThursdayAug 15, 2024 11:04 am

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports Q2 2024 Financial Results, Shares Business Update

Scinai Immunotherapeutics (NASDAQ: SCNI) is a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit. The company today published its financial results for the second quarter ended June 30, 2024, and provided a business update. Scinai plans to host a webinar to discuss its Q2 2024 results and business update on August 20, 2024, at 11 a.m. EDT/6 p.m. Israel Time. Recent highlights from Q2 2024 included the signing of an agreement to restructure a $29 million bank loan to equity and plans to regain Nasdaq compliance by…

Continue Reading

ThursdayAug 15, 2024 9:55 am

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Announces Q2 2024 Financial Results, Provides Update Showing ‘Productive’ Recent Months

Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today released financial results for its second quarter ended June 30, 2024, and provided a business update. According to the update, results from the company’s completed Phase 2/3 AD study showed that buntanetap significantly improved cognition in patients with early AD. Additionally, data from its Phase 3 PD study revealed that buntanetap led to improvements in both the Unified Parkinson’s Disease Rating Scale (“MDS-UPDRS”) and cognition across several PD subpopulations. The company also discussed the filing of patents, team…

Continue Reading

WednesdayAug 14, 2024 3:03 pm

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Given $21.00 Price Target by EF Hutton

Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), recently had its price target set at $21.00. The price target was issued by Jason Kolbert from EF Hutton on August 13, 2024. At the time of the announcement, Annovis Bio was trading at $7.87. “The overall price target consensus is at $26.00 with high price of $26.00, low price of $26.00, and median price is at $26.00,” the report reads. To view the full report, visit https://ibn.fm/pXhe9 About Annovis Bio Inc. Annovis Bio is headquartered in Malvern, Pennsylvania,…

Continue Reading

WednesdayAug 14, 2024 1:55 pm

BioMedNewsBreaks — NextPlat Corp. (NASDAQ: NXPL), Progressive Care (RXMD) Release Q2 2024 Financial Results Showing 474% Revenue Increase

NextPlat (NASDAQ: NXPL), a global e-Commerce provider, has released record financial results for its second fiscal quarter, the period ended June 30, 2024; the results include the consolidation of the operations of its e-commerce business with the results of its healthcare operations, Progressive Care Inc. (OTCQB: RXMD). Highlights of the report indicate the company experienced a 474% increase in consolidated Q2 revenues, which totaled $17 million, and a record 34.2% quarterly margins; the report noted that the company anticipates reaching $70 million in 2024 annual revenues with additional healthcare services contracts and E-commerce expansion expected to drive the company’s continued growth. “We are…

Continue Reading

WednesdayAug 14, 2024 9:00 am

BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Reports Concussion Drug Stable Across Wide Range of Temps

Oragenics (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, recently completed the synthesis of its ONP-002 drug batch for its upcoming planned phase 2 clinical trial. Consequently, the company is reporting that ONP-002, its lead candidate for treating concussion, is stable across a wide temperature range, thus eliminating the need for cumbersome cold storage during transport and storage. Specifically, the company reported three-month stability with more than 99% purity at temperatures ranging from -20°C to 104°C. “We understand the importance of getting ONP-002 into the brain quickly after concussive injury to…

Continue Reading

TuesdayAug 13, 2024 10:13 am

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Signs Definitive Loan Restructuring Agreement with EIB Converting Debt into Equity

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit, today announced the signing of a definitive Loan Restructuring Agreement with the European Investment Bank (“EIB”), its lender. The agreement also included an amendment and restatement to the Finance Contract between the parties. According to the announcement, an amount equal to approximately €26.6 million (approximately $29 million), including interest accrued to date, owned by Scinai to EIB under the finance contract, will be converted into 1,000 preferred shares, no par value per share, of…

Continue Reading

MondayAug 12, 2024 10:57 am

BioMedNewsBreaks – HealthLynked Corp. (HLYK) Partners with RxSpark to Provide Integrated Solution for Medication Management

HealthLynked (OTCQB: HLYK), a trailblazer in healthcare technology, today announced a strategic partnership with RxSpark, a platform dedicated to providing affordable prescription medications and healthcare services. According to the announcement, this partnership will enhance the patient’s experience by integrating HealthLynked’s advanced healthcare network with RxSpark’s pharmacy discounts and prescription price comparison tool. Through this exciting integration, HealthLynked members can find savings of up to 90% off their medications, easily manage their prescriptions, and ensure timely access to necessary medications. Key benefits include enhanced prescription management, improved access to affordable medications, streamlined healthcare experience, and cost savings for patients. “At HealthLynked,…

Continue Reading

ThursdayAug 08, 2024 2:00 pm

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), is reporting new preclinical data regarding buntanetap, its lead compound. According to the report, the date demonstrates the synergistic effect of buntanetap when combined with the glucagon-like peptide 1 (“GLP-1”) agonist dulaglutide (Trulicity[R]) in a mouse model of Alzheimer’s disease. The announcement noted that the Alzheimer’s Disease Diagnostics and Therapeutics Market size is projected to reach $7.7 billion this year and grow to $10.1 billion by 2029. Major factors contributing to that growth include the increasing use…

Continue Reading